4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 2023 NACFCGlobeNewsWire • 10/25/23
4DMT Receives EMA Priority Medicines (PRIME) Designation for 4D-150 Clinical-Stage Genetic Medicine for Treatment of Wet AMDGlobeNewsWire • 10/23/23
4DMT Announces First Patient Enrolled in 4D-150 Phase 2 SPECTRA Clinical Trial in DME, and Expansion of 4D-150 Phase 2 Stage in PRISM Clinical Trial in Wet AMDGlobeNewsWire • 09/07/23
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/09/23
4D Molecular Therapeutics Reports Second Quarter 2023 Financial Results and Operational HighlightsGlobeNewsWire • 08/09/23
4DMT Presents Additional Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ASRS 2023GlobeNewsWire • 07/29/23
4DMT Completes Enrollment of Phase 2 PRISM Clinical Trial for Intravitreal 4D-150 in Patients with Wet AMD and Reports Interim Safety and Tolerability DataGlobeNewsWire • 07/17/23
Astellas and 4D Molecular Therapeutics (4DMT) Enter into License Agreement to Use 4DMT's Proprietary Intravitreal R100 Vector for Rare Ophthalmic TargetsPRNewsWire • 07/10/23
4D Molecular Therapeutics: Pioneering Gene Therapies And An Impressive Fiscal PerformanceSeeking Alpha • 07/10/23
4DMT Presents Positive Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial in Patients with Cystic Fibrosis at the ECFS 46th Annual MeetingGlobeNewsWire • 06/07/23
4DMT to Present Interim Data from 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis Lung Disease at the European Cystic Fibrosis Society (ECFS) 46th Annual MeetingGlobeNewsWire • 05/24/23
4DMT Announces Presentation on Aerosolized 4D-710 for Treatment of Cystic Fibrosis at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual MeetingGlobeNewsWire • 05/11/23
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/10/23
4D Molecular Therapeutics Reports First Quarter 2023 Financial Results and Operational HighlightsGlobeNewsWire • 05/10/23
4D Molecular Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 05/09/23
4D Molecular Therapeutics, Inc. (FDMT) Surges 5.4%: Is This an Indication of Further Gains?Zacks Investment Research • 05/08/23
4DMT Presents Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ARVO 2023GlobeNewsWire • 04/27/23
4DMT Acquires Complement Pathway Inhibitor Payload for 4D-175 Product Candidate for Geographic AtrophyGlobeNewsWire • 04/24/23
4D Molecular Therapeutics, Inc. (FDMT) Soars 11.2%: Is Further Upside Left in the Stock?Zacks Investment Research • 04/14/23
4DMT to Present Interim Data from 4D-150 Phase 1/2 PRISM Clinical Trial for Wet AMD at ARVO 2023, and Promotes Robert Kim, M.D. to Chief Medical OfficerGlobeNewsWire • 04/13/23